Good morning :)
$
₹
Beam Therapeutics Inc

Beam Therapeutics Inc

BEAM

NASDAQ
Asset Logo

Beam Therapeutics Inc

BEAM

NASDAQ
$27.795.57% (+1.46)
$
₹
$27.795.57% (+1.46)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Mid Cap

With a market cap of $2.7B the stock is ranked 1909

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

2.63
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.68
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-55.45%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 15 analysts reports

Buy
13 analysts
Hold
2 analysts
Sell
0 analyst

Price Upside

+90.9%

Earnings Growth

-341.16%

Rev. Growth

-61.92%

See Detailed Forecast

Company Profile

Company Profile

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
50.67
50.67
1Y Return
36.27%
36.27%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.90
28.90
1Y Return
58.2%
58.2%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
37.21%
37.21%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
32.21
32.21
1Y Return
24.59%
24.59%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.24
21.24
1Y Return
51.74%
51.74%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 90.90% growth, versus a trailing 3-year CAGR of 1.84%.

2026
Current$25.87Baseline
Analyst Target - 1 year
Target$49.38+90.9%

All values in $

202220232024202520262027$30.32$38.32$46.32Target+90.9%
2026
Current$25.87Baseline
Analyst Target - 1 year
Target$49.38+90.9%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies -61.92% growth, versus a trailing 3-year CAGR of 31.88%.

2025
Current$139.74Baseline
Forecast for Dec 2026
High$100-28.44%
Average$53.21-61.92%
Low$0-100%

All values in $ Million

20212022202320242025202651.8460.92377.7063.51139.74Low-100%Average-61.92%High-28.44%
2025
Current$139.74Baseline
Forecast for Dec 2026
High$100-28.44%
Average$53.21-61.92%
Low$0-100%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-1.01Baseline
Forecast for Dec 2026
High$-4.24-319.64%
Average$-4.46-341.16%
Low$-4.76-371.5%

All values in $

202120222023202420252026-5.95-4.13-1.9-4.58-1.01Low-371.5%Average-341.16%High-319.64%
2025
Current$-1.01Baseline
Forecast for Dec 2026
High$-4.24-319.64%
Average$-4.46-341.16%
Low$-4.76-371.5%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

9.6
-112.7
114.1
244.2
31.7
-94.3
0.4
-122.6
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue7.4111.7714.2630.067.478.469.69114.1031.730.49
Net Income-98.66-91.05-96.66-90.35-109.27-102.29-112.72244.29-94.31-122.67
Net Profit Margin-1331.56%-773.45%-677.46%-300.50%-1462.78%-1208.25%-1162.38%214.09%-297.17%-25036.32%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Beam Therapeutics Inc -2.63-
AbbVie Inc50.6750.450.60
Amgen Inc28.9021.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare BEAM with any stock or ETF
Compare BEAM with any stock or ETF
Comparing from
BEAM
ABBV
AMGN
Loading...

Frequently asked questions

  1. Beam Therapeutics Inc (BEAM) share price today is $27.79 as of November 5, 2026 at 2:29 AM IST. The stock touched a day high of $27.92 and a day low of $26.28.

  2. Beam Therapeutics Inc stock trades on NASDAQ under the ticker symbol BEAM.

  3. Beam Therapeutics Inc's market capitalization is $2.67B as of November 5, 2026 at 2:29 AM IST.

  4. Beam Therapeutics Inc's price-to-earnings (P/E) ratio is N/A as of November 4, 2026.

  5. Beam Therapeutics Inc's price-to-book (P/B) ratio is 2.63 as of November 4, 2026.

  6. Yes, You can buy Beam Therapeutics Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Beam Therapeutics Inc shares in three steps: 1. Search Beam Therapeutics Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Beam Therapeutics Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Beam Therapeutics Inc (BEAM) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.3597 shares at the current price of $27.79.

Loading...